Medicenna Therapeutics Corp.
MDNAF
$0.32
$0.0310.35%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.99M | 4.00M | 3.98M | 4.31M | 4.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.17M | 15.97M | 15.60M | 15.68M | 14.65M |
| Operating Income | -16.17M | -15.97M | -15.60M | -15.68M | -14.65M |
| Income Before Tax | -13.28M | -9.41M | -9.99M | -9.50M | -8.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.28 | -9.41 | -9.99 | -9.50 | -8.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.28M | -9.41M | -9.99M | -9.50M | -8.59M |
| EBIT | -16.17M | -15.97M | -15.60M | -15.68M | -14.65M |
| EBITDA | -16.15M | -15.94M | -15.56M | -15.64M | -14.62M |
| EPS Basic | -0.16 | -0.11 | -0.12 | -0.12 | -0.11 |
| Normalized Basic EPS | -0.10 | -0.07 | -0.08 | -0.07 | -0.07 |
| EPS Diluted | -0.16 | -0.11 | -0.12 | -0.12 | -0.11 |
| Normalized Diluted EPS | -0.10 | -0.07 | -0.08 | -0.07 | -0.07 |
| Average Basic Shares Outstanding | 332.76M | 327.54M | 322.13M | 315.56M | 306.66M |
| Average Diluted Shares Outstanding | 332.76M | 327.54M | 322.13M | 315.56M | 306.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |